INHIBITOR OF SYNTHESIS OF TUMOR NECROSIS FACTOR-Α, PENTOXIFYLLINE, IN COMBINED THERAPY OF THE CHRONIC HEART FAILURE
Abstract
Aim. To study effects of pentoxifylline in combination with basic therapy on functional status, intracardiac hemodynamics, neurohormones and proinflammatory cytokines levels in patients with chronic heart failure (CHF) complicated ischemic heart disease (IHD).
Material and methods. 55 patients with CHF complicated IHD (83,6% men and 16,4% women) were involved in the study. Duration CHF was 2,4 years in average. Class I of CHF (NYHA) was registered in 5 patients (9,1 %), class II - in 33 patients (60,0 %), class III - in 16 patients (29,1 %), class IV in 1 patient (1,8 %). Dynamics of life quality, severity of clinical status, functional reserve, intracardiac hemodynamics, neurohormones and proinflammatory cytokines levels was assessed during 9 months of therapy.
Results. Pentoxifylline, added to standard therapy of CHF, resulted in improvement of life quality, intracardiac hemodynamics and clinical status of the patients with CHF of I-II class (NYHA). Besides reduction in proinflammatory cytokine (tumor necrosis factor-α, interleukin-6) and neuronhormone levels was found in patients with CHF of I-II class.
Conclusion. Pentoxifylline can be useful in combined therapy of CHF
About the Authors
O. P. Dudarenko
Moscow State Medical Stomatological University
Russian Federation
Department of clinical functional diagnostics
Russian Federation
Department of clinical functional diagnostics
E. L. Shkol’nik
Moscow State Medical Stomatological University
Russian Federation
Department of clinical functional diagnostics
Russian Federation
Department of clinical functional diagnostics
Moscow State Medical Stomatological University
Russian Federation
Department of clinical functional diagnostics
Russian Federation
Department of clinical functional diagnostics
Moscow State Medical Stomatological University
Russian Federation
Department of clinical functional diagnostics
Russian Federation
Department of clinical functional diagnostics
Moscow State Medical Stomatological University
Russian Federation
Department of clinical functional diagnostics
Russian Federation
Department of clinical functional diagnostics
References
1. Агеев Ф.Т., Даниелян М.О., Мареев В.Ю., Беленков Ю.Н. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА-О-ХСН). Журнал Сердечная недостаточность 2004;5(3):4-7.
2. Беленков Ю.Н., Мареев В.Ю. Принципы рационального лечения сердечной недостаточности. М.: Медиа Медика; 2000.
3. Васюк Ю.А., Ющук Е.А., Хадзегова А.Б., и др. Гибернирующий миокард и процессы постинфарктного ремоделирования. Сердечная недостаточность 2001;4:181-6.
4. Насонов Е.Л., Самсонов М.Ю., Беленков Ю.Н., Фукс Д. Иммунопатология застойной сердечной недостаточности: роль цитокинов. Кардиология 1999;(3):66-73.
5. Ольбинская Л.И., Игнатенко С.Б. Патогенез и современная фармакотерапия хронической сердечной недостаточности. Сердечная недостаточность 2002;2(12):88-91.
6. Трофимов Е.С., Смурова Ю.В. Оценка тяжести хронической сердечной недостаточности с использованием медиаторов воспаления. Вестник РГМУ 2007;2(55):49.
7. Поскребышева А.С., Шостак Н.А., Смурова Ю.В. Исследование провоспалительных цитокинов, катехоламинов и мозгового натрийуретического пептида у больных ишемической и ревматической болезнью сердца, осложнённой хронической сердечной недостаточностью. Тез. I общероссийского съезда и V ежегодной конференции ОССН "Сердечная недостаточность 2004". Сборник трудов; Москва 2004. С.22.
8. Cычев А.В., Насонова С.Н., Насонов Е.Л., и др.. Влияние стандартной терапии хронической сердечной недостаточности в сочетании с пентоксифиллином на клинико-функциональный статус и иммунные системы больных с хронической сердечной недостаточностью. Тез. I общероссийского съезда и V ежегодной конференции ОССН "Сердечная недостаточность 2004". Сборник трудов; Москва 2004. С.21- 22
9. Bergman M.R., Holycross B.J. Pharmacological modulation of myocardial tumor necrosis factor a production phosphodiesterasa inhibitore. Pharmacol Exp Ther 1996;44:247-54.
10. Blam M.E., Steil R.B., Lichtenstein G.R. Intergraiting anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol 2001;96:1977-97.
11. Blum A., Miller H. Pathophisiological role of cytokines in congestive heart failure. Annu Rev Med 2001;52:15-27.
12. Bolli R. Mechanism of Myocardial “Stunning”. Circulation 1990;82:723- 38.
13. Conraads V.M., Bosmans J.M., Vrints C.J. Chronic heart failure: an example of a systemic chronic inflammatory disease resulting in cachexia. Int J Cardiol 2002;85(1):33-49.
14. Feldman A., Young J., Bourge R. et al. Mechanism of increased mortality from vesnarinone in the severe heart failure. J Am Coll Cardiol 1997; 29(Suppl A):64A.
15. Feldman A.M., Brostow M.R., Parmley W.W., et al. Effects of vesnarinone on norbidity and mortality in patients with heart failure. New Engl J Med 1993; 329: 149-55.
16. Francis G.S. Pathophysiology of chronic heart failure. Am J Med 2001; 110(Suppl 7A):37-46.
17. Jessup M., Brozena S. Heart failure. N Engl J Med 2003;348:2007- 2018.
18. Krum H. Tumor necrosis factor alpha blockade as a therapeutic strategy in heart failure (RENEWAL and ATTACH): unsuccessful to be specific. J Cardiac Failure 2002;6:8.
19. Munger M., Johnson B., Amber I.J., et al.. Circulating concentrations of proinflammatory cytokines in the mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996;77:723-7.
20. Schobersberg W., Hoffman G., Hobisch-Hagen P., et al. Neopterin and 78-dihydroneopterin induce apoptosis in the rat alveolar epithelial cell line. FEBS Lett 1996;397:263-8.
21. Sliwa K., Skudicky D., Candy G., et al. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic cardiomyopathy. Lancet 1998;351:1091-3.
22. Sliwa K., Woodiwiss A., Candy G., et al. Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 2002;90(10):1118-22.
23. Sliwa K., Woodiwiss A., Kone V.N., et al. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation 2004; 109(6):750-5.
24. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-6.
25. Torre-Amione G., Kapadia S., Lee J. et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995;92(6):1487-93.
26. Torre-Amione G., Kapadia S., Lee J., Durand J.B., Bies R.D., Young J.B. et al. Tumor necrosis factor-a and tumor necrosis factor receptors in the failing heart. Circulation 1996; 93: 704-711.
27. Torre-Amione G., Stetson S.S., Farmer J.A. Clinical implications of tumor necrosis facror a antagonist in patients with congestive heart failure. Ann Rheum Dis 1999;58(Suppl 1):1103-6.
28. Tsutamoto T., Hisanaga T., Wada A., et al. Plasma concentration of interleukin-6 as a marker of prognosis in patients with chronic heart failure. Circulation 1994; 90 (Suppl I): 381.
29. Waage A., Sorensen M., Stordal B. Differential effect of oxpentifylline on tumour necrosis factor and interleukin-6 production. Lancet 1990;335:543.
Review
For citations:
Dudarenko O.P., Shkol’nik E.L., , , INHIBITOR OF SYNTHESIS OF TUMOR NECROSIS FACTOR-Α, PENTOXIFYLLINE, IN COMBINED THERAPY OF THE CHRONIC HEART FAILURE. Rational Pharmacotherapy in Cardiology. 2008;4(2):6-12. (In Russ.)
Views:
647
Email this article 